logo-loader
viewDestiny Pharma plc

Destiny Pharma awaits key inflection point mid--2020 in its antimicrobial Phase 2b clinical trial

Destiny Pharma (LON:DEST) CEO Neil Clark spoke with Proactive at the Biotech Showcase 2020 in San Francisco. The UK-based, clinical phase biotechnology company is focused on preventing post-surgical infection in a Phase 2b clinical trial with its lead asset. According to its website, Destiny is building a portfolio of antimicrobial drug products that to combat the threat of antimicrobial resistance (AMR).

Quick facts: Destiny Pharma plc

Price: 41.5 GBX

AIM:DEST
Market: AIM
Market Cap: £18.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Crossword Cybersecurity 'cautiously optimistic' on 2020 as first half...

Crossword Cybersecurity PLC's (LON:CCS) Mary Dowd tells Proactive London's Andrew Scott they're cautiously optimistic on hitting full year targets after first half revenues to June 2020 rose 18%. The company expects to report revenues of £674,000 while it closed off the period with £1.6mln in...

14 hours, 42 minutes ago

2 min read